An analyst from Morgan Stanley initiated coverage of Becton Dickinson (NYSE: BDX) at 'overweight' with a price target of $295.00. Prior to this rating, Becton Dickinson had 12 buy...
BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the new BD...
A Barclays analyst maintained Becton Dickinson (NYSE: BDX) at Overweight and a price target of $284.00 from a prior price target of %currency%%price%. Prior to this rating, Becton...
A Citi analyst maintained Becton Dickinson (NYSE: BDX) at Neutral and a price target of $260.00 from a prior price target of %currency%%price%. Prior to this rating, Becton Dickinson had...
A TD Cowen analyst maintained Becton Dickinson (NYSE: BDX) at Market Perform and a price target of $271.00 from a prior price target of %currency%%price%. Prior to this rating, Becton...
Investing.com - Becton Dickinson (NYSE: BDX) reported second quarter EPS of $2.86, $0.12 better than the analyst estimate of $2.74. Revenue for the quarter came in at $4.8B versus the...
Becton Dickinson (NYSE:BDX) declared a quarterly dividend of $0.91 per share, or $3.64 annualized.The dividend will be payable on June 30, 2023, to stockholders of record on June 9, 2023,...
By Sam Boughedda KeyBanc Capital Markets analysts upgraded shares of Becton Dickinson (NYSE:BDX) to Overweight from Sector Weight with a price target of $304 per share in a note to clients...
KeyBanc has upgraded Becton, Dickinson, and Company (NYSE: BDX) with a price target of $304. The analyst writes that BDX is progressing toward increasing the overall WAMGR of its portfolio...
A KeyBanc analyst upgraded Becton Dickinson (NYSE: BDX) from Sector Weight to Overweight with a price target of $304.00. Prior to this rating, Becton Dickinson had 9 buy ratings, 6 hold...
A Morgan Stanley analyst maintained Becton Dickinson (NYSE: BDX) at Overweight and a price target of $252.00. Prior to this rating, Becton Dickinson had 10 buy ratings, 7 hold ratings,...
BD (BDX) received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD Vaginal Panel on the BD COR™ System, a comprehensive diagnostic test that directly detects the...
BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today announced U.S. Food and Drug Administration (FDA) market approval for the BD Onclarity™ HPV Assay...
Becton Dickinson (BDX) reported Q1 EPS of $2.98, $0.30 better than the analyst estimate of $2.68. Revenue for the quarter came in at $4.6 billion versus the consensus estimate of $4.54...
Investing.com - Becton Dickinson (NYSE: BDX) reported first quarter EPS of $2.98, $0.30 better than the analyst estimate of $2.68. Revenue for the quarter came in at $4.6B versus the...
By Geoffrey Smith Investing.com -- The dollar falls to a nine-month low and Treasury yields ease after the Federal Reserve signals the end is near for the current rate hiking cycle. The...
By Sam Boughedda Shares of Becton Dickinson (NYSE:BDX) are up more than 4% Thursday on the back of its fiscal fourth-quarter earnings release, which saw it top revenue estimates. The...
Investing.com - Becton Dickinson (NYSE:BDX) reported on Thursday fourth quarter {{erl-8067||earnings that matched analysts' forecasts and revenue that topped expectations. Becton Dickinson...
Becton Dickinson (BDX) reported Q4 EPS of $2.75, in-line with the analyst estimate of $2.75. Revenue for the quarter came in at $4.8 billion versus the consensus estimate of $4.72...
Becton Dickinson (NYSE:BDX) reported Q3 EPS of $2.66, $0.16 better than the analyst estimate of $2.50. Revenue for the quarter came in at $4.6 billion versus the consensus estimate of $4.47...
Investing.com - Becton Dickinson (NYSE:BDX) reported on Thursday third quarter {{erl-8067||earnings that beat analysts' forecasts and revenue that topped expectations. Becton Dickinson...
By Sam Boughedda Shares of Becton, Dickinson and Company (NYSE:BDX) were upgraded to Overweight from Equal Weight by Wells Fargo analyst Larry Biegelsen on Friday. Biegelsen has a $295 price...
Pre-Open Stock Movers:Zendesk, Inc. (NYSE:ZEN) 30% HIGHER; entered into a definitive agreement to be acquired by an investor group led by leading global investment firms Permira and Hellman...
By Sam Boughedda Becton, Dickinson and Company (NYSE:BDX) announced Monday that it has agreed on a deal with Frazier Healthcare Partners to acquire Parata Systems, a provider of pharmacy...
Becton Dickinson (NYSE:BDX) reported Q2 EPS of $3.18, $0.19 better than the analyst estimate of $2.99. Revenue for the quarter came in at $5 billion versus the consensus estimate of $4.85...
Investing.com - Becton Dickinson (NYSE:BDX) reported on Thursday second quarter {{erl-8067||earnings that beat analysts' forecasts and revenue that topped expectations. Becton Dickinson...
Investing.com - Becton Dickinson (NYSE:BDX) reported on Thursday first quarter {{erl-8067||earnings that beat analysts' forecasts and revenue that topped expectations. Becton Dickinson...
Investing.com - Becton Dickinson (NYSE:BDX) reported on Thursday fourth quarter {{erl-8067||earnings that beat analysts' forecasts and revenue that topped expectations. Becton Dickinson...
Investing.com - Becton Dickinson (NYSE:BDX) reported on Thursday third quarter {{erl-8067||earnings that beat analysts' forecasts and revenue that topped expectations. Becton Dickinson...
Investing.com – U.S. equities were lower at the close on Monday, as losses in the Technology, Consumer Services and Consumer Goods sectors propelled shares lower. At the close in NYSE, the...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
